At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 27 enrolled
Drug / intervention
ICL670drug
Likely dose
ICL670 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.
In Brief
A Phase 4 clinical trial evaluating ICL670 for Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major. Completed, enrolled 27 participants across 6 sites.
Detailed Summary
This was a prospective, single-arm, multicenter, national, phase II clinical study. The purpose of this Phase II study was to examine the safety and efficacy of deferasirox to decrease iron overload (IOL) in the posttransplant period in patients with beta-thalassemia major.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartSep 2013
Primary CompletionOct 2015
TodayJul 2026
First PostedJun 4, 2012
Enrollment StartSep 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.1 years ago
Interventions
ICL670drug
Oral dose of ICL670 at 10 mg/kg daily